BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abdel-Ghaffar TY, Sira MM, El Naghi S. Hepatitis C genotype 4: The past, present, and future. World J Hepatol 2015; 7(28): 2792-2810 [PMID: 26668691 DOI: 10.4254/wjh.v7.i28.2792] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 El-Tahan RR, Ghoneim AM, Zaghloul H. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients. Virus Genes 2020;56:564-81. [PMID: 32572756 DOI: 10.1007/s11262-020-01776-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
3 Mattar EH, Almehdar HA, Uversky VN, Redwan EM. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4. Mol Biosyst 2016;12:2785-97. [PMID: 27327492 DOI: 10.1039/c6mb00283h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
5 Camus G, Han B, Asselah T, Hsieh D, Dvory-Sobol H, Lu J, Svarovskaia E, Martin R, Parhy B, Miller MD, Brainard DM, Kersey K, Abergel A, Mo H. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. J Viral Hepat 2018;25:134-43. [PMID: 28984067 DOI: 10.1111/jvh.12795] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
6 Ali NK, Mohamed RR, Saleh BE, Alkady MM, Farag ES. Occult hepatitis C virus infection among haemodialysis patients. Arab J Gastroenterol. 2018;19:101-105. [PMID: 30245116 DOI: 10.1016/j.ajg.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tarragô AM, Pereira GL, Victória FDS, Marie AMA, Victória MB. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Rev Soc Bras Med Trop 2017;50:861-3. [PMID: 29340469 DOI: 10.1590/0037-8682-0094-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
9 Boeke CE, Hiebert L, Waked I, Tsertsvadze T, Sharvadze L, Butsashvili M, Zakalashvili M, Naing W, Gupta N, Kateera F, McClure C, Ward JW, Ramers CB. Retreatment of Chronic Hepatitis C Infection: Real-World Regimens and Outcomes from National Treatment Programs in Three Low- and Middle-Income Countries. Clin Infect Dis 2021:ciab461. [PMID: 34014252 DOI: 10.1093/cid/ciab461] [Reference Citation Analysis]
10 Ragab D, Samaha D, Mohamed N, Rafik M, Abdel Hady W. Chronic hepatitis C virus infection impairs natural killer cells-dendritic cells cross-talk: An in vitro culture study. Microbiol Immunol 2021;65:76-84. [PMID: 33150993 DOI: 10.1111/1348-0421.12858] [Reference Citation Analysis]
11 Ibrahim ES, Abdel-Samiee M, Youssef MI, El-Shazly H, A El-Gendy AE, Sakr AA, Elwazzan D, Nassar MR, Aly Elshormilisy A, Madkour A, Kamal M, Amrousy YM, Elkhadry SW, Abdelsameea E. Variceal recurrence 4 years post endoscopic band ligation in hepatitis C patients who achieved sustained virological response with oral direct-acting antiviral therapy. J Viral Hepat 2021;28:279-87. [PMID: 33098209 DOI: 10.1111/jvh.13426] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Boerekamps A, Vanwolleghem T, van der Valk M, van den Berk GE, van Kasteren M, Posthouwer D, Dofferhoff ASM, van Hoek B, Ramsoekh D, Koopsen J, Schinkel J, Florence E, Arends JE, Rijnders BJ. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study). J Hepatol 2019;70:554-7. [PMID: 30527953 DOI: 10.1016/j.jhep.2018.10.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Nagaty A, Abd El-Wahab EW. Real-life results of sofosbuvir based therapy in chronic hepatitis C -naïve and -experienced patients in Egypt. PLoS One 2017;12:e0184654. [PMID: 28981513 DOI: 10.1371/journal.pone.0184654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
14 Daw MA, El-Bouzedi A, Ahmed MO, Dau AA, Agnan MM; In association with the Libyan Study Group of Hepatitis & amp; HIV. Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa. Travel Med Infect Dis. 2016;14:517-526. [PMID: 27502972 DOI: 10.1016/j.tmaid.2016.05.020] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
15 Coppola N, Alessio L, Onorato L, Sagnelli C, Macera M, Sagnelli E, Pisaturo M. Epidemiology and management of hepatitis C virus infections in immigrant populations. Infect Dis Poverty 2019;8:17. [PMID: 30871599 DOI: 10.1186/s40249-019-0528-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
16 Chouikha A, Khedhiri M, Triki H, Hammemi W, Sadraoui A, Touzi H, Ben Yahia A, Chtourou A, Gargouri S, Feki Ben Rajah L, Hakim Karray H, Triki H. Focus on hepatitis C virus genotype distribution in Tunisia prior to elimination: a 16-year retrospective study. Arch Virol 2021;166:501-10. [PMID: 33394169 DOI: 10.1007/s00705-020-04918-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Bell AM, Wagner JL, Barber KE, Stover KR. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. Int J Hepatol. 2016;2016:3852126. [PMID: 27403342 DOI: 10.1155/2016/3852126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
18 Sanchez Antolin G, Testillano M, Pascasio JM, Narvaez Rodriguez I, Prieto M, Otero A, Herrero JI, Londoño M, Fernandez Vazquez I, Castells L; Spanish Society of Liver Transplantation Study Group Collaborating Group. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplant Proc 2016;48:3013-6. [PMID: 27932134 DOI: 10.1016/j.transproceed.2016.08.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
19 Aboushady M, Alwassief A, Abdelrazik M, Ziada D, Shahba H, Elmestikawy A, Elbahrawy A. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. J Interferon Cytokine Res 2019;39:539-46. [PMID: 31173550 DOI: 10.1089/jir.2019.0041] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
20 Kirdar S, Aydin N, Tiryaki Y, Ertugrul B, Coskun A, Bilgen M. Dynamics of HCV epidemiology in Aydin province of Turkey and the associated factors. APMIS 2018;126:109-13. [PMID: 29271117 DOI: 10.1111/apm.12790] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Mariño A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. J Acquir Immune Defic Syndr 2016;73:149-53. [PMID: 27258234 DOI: 10.1097/QAI.0000000000001097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Hassanien KS, El-Sayed EM, Ismail RS, Zakarya ZM, Helal GK. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients. J Clin Pharm Ther 2021;46:942-9. [PMID: 33768560 DOI: 10.1111/jcpt.13417] [Reference Citation Analysis]
23 Mosaad YM, Metwally SS, Farag RE, Lotfy ZF, Abdeltwab HE. Association between Toll-Like Receptor 3 ( TLR3 ) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV. Immunological Investigations 2019;48:321-32. [DOI: 10.1080/08820139.2018.1527851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
24 Khalifa RH, Shahin RMH, Aboukhalil REE, Marie MA, El-Deeb AM, Riad NM. Digging more in the genetic risk prediction of hepatitis C virus epidemic in Egypt: Apoptosis genes polymorphisms in the susceptibility of hepatitis C virus and association with viral load. Virus Res 2017;238:35-9. [PMID: 28587866 DOI: 10.1016/j.virusres.2017.05.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
25 El-Tahan RR, Ghoneim AM, Zaghloul H. 5' UTR and NS5B-based genotyping of hepatitis C virus in patients from Damietta governorate, Egypt. J Adv Res 2018;10:39-47. [PMID: 30046475 DOI: 10.1016/j.jare.2018.01.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]